CAMBRIDGE, Mass -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced preliminary data from the first part of a Phase 2 clinical study conducted by the Company of IMO-2055 monotherapy in ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced favorable safety and efficacy results from a Phase 1b study of IMO-2055, a TLR9 agonist, in combination ...
The U.S. National Chemistry Olympiad Program is proud to announce the 20 finalists who will participate in the Chemistry Olympiad Study Camp, June 1-14, 2025 at the University of Maryland College Park ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback